Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Impax Pharmaceuticals

Division of Impax Laboratories Inc.

Latest From Zeneca Group PLC

INTERVIEW: Faron Chairman Discusses Bettering Pharma's Reputation And Having No Regrets

Frank Armstrong is an industry veteran with no intention of slowing down. Over his 30-year career, he has held CEO roles with five biotechnology companies and led medical science and innovation at Merck Serono, and was previously executive vice president of product development at Bayer and senior vice president of medical research and communications at Zeneca. He now chairs the Finnish pharma company Faron's board and has high hopes for its drug Traumakine.

Therapy Areas Respiratory

Sweden’s Reference Pricing Proposal: A Five-Year Doomsday Clock For Innovation?

Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.

BioPharmaceutical Europe

Have Problem? Try M&A.

M&A was the universal prescription for the medical industry in 1998 as acquisition dollar volumes hit record levels. For some, the dealmaking further separates the haves and have-nots. For others, it's an addictive drug for coping with chronic insufficiency syndrome. But for nearly everyone who's using it, M&A is the easiest, if not always an effective, answer to the increasingly intractable problem of growth.
BioPharmaceutical Medical Device

Outsourcing: Hoechst's New Approach to Cost Cutting

Eager to join the pharmaceutical elite, Hoechst needs to cut costs without creating more labor unrest. As it merges with Rhône-Poulenc into Aventis, HMR is outsourcing all US development to the CRO, Quintiles, looking to cut costs by $100 million over five years and provide a benchmark for the rest of HMR's worldwide development program. Moreover, both Quintiles and HMR hope to use the collaboration, perhaps in tandem with outside investors, to fund additional development projects; Quintiles would be assured the development work, and receive some of the drug's upside; HMR would be able to delay its own buy-in decisions until the projects had generated more actionable data. But the deal raises conflict-of-interest questions: will Quintiles' other clients shy away from a company with extra incentives to develop particular drugs-either those in which it has an equity interest or those of a client with whom it has a special relationship?
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Impax Laboratories Inc.
  • Senior Management
  • Michael Nestor, Pres.
    Suneel Gupta, PhD, CSO
    Shawn Fatholahi, VP, Sales & Mktg.
    David Paterson, PhD, VP, Bus. Dev.
  • Contact Info
  • Impax Pharmaceuticals
    Phone: (510) 240-6000
    31047 Genstar Rd.
    Hayward, CA 94544